Methotrexate
Olokizumab plus methotrexate safe, efficacious through 106 weeks in rheumatoid arthritis
Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.
Corticosteroids
Pharmacotherapy and Management Guidelines
Pharmacotherapeutic Options
VIDEO: 'Exciting time' for therapeutic options in polymyalgia rheumatica
In this video, Sebastian E. Sattui, MD, MS, discusses currently available and emerging treatment options in polymyalgia rheumatica.
Two-week methotrexate pause helps COVID booster response without significant flares
In patients with immune-mediated inflammatory diseases, a 2-week pause of methotrexate after receiving a COVID-19 vaccine booster yielded a sustained, significantly increased antibody response, without serious flares, according to a study.
Autoimmune thyroid disease risk decreases after rheumatoid arthritis diagnosis
Adults have a decreased risk for developing autoimmune thyroid disease after being diagnosed with rheumatoid arthritis, with the risk even lower for those receiving disease-modifying antirheumatic drugs, according to study data.
VIDEO: ‘Practice affirming’ findings from split-dosing methotrexate study at ACR
SAN DIEGO — In this video, Healio spoke with Jeffrey A. Sparks, MD, MMSc, results from a study conducted in India assessing the efficacy of treating rheumatoid arthritis with split-doses of methotrexate.
Triple combination therapy ‘superior to monotherapy,’ improves remission in Crohn’s
A combination of vedolizumab, adalimumab and methotrexate resulted in endoscopic remission at week 26 in more than a third of patients with Crohn’s disease, according to data in Clinical Gastroenterology and Hepatology.
VIDEO: Efficacious split-dosing of high-dose methotrexate in patients with RA
SAN DIEGO — In this video, Healio spoke with Kathryn Dao, MD, about the SMART study presented at ACR Convergence 2023.